These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 25936315)
1. Immunoadsorption with regenerating systems in neurological disorders --A single center experience. Hohenstein B; Passauer J; Ziemssen T; Julius U Atheroscler Suppl; 2015 May; 18():119-23. PubMed ID: 25936315 [TBL] [Abstract][Full Text] [Related]
5. Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity. Biesenbach P; Schmaldienst S; Smolen JS; Hörl WH; Derfler K; Stummvoll GH Atheroscler Suppl; 2009 Dec; 10(5):114-21. PubMed ID: 20129388 [TBL] [Abstract][Full Text] [Related]
6. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden. Dittrich-Riediger J; Schatz U; Hohenstein B; Julius U Atheroscler Suppl; 2015 May; 18():45-52. PubMed ID: 25936304 [TBL] [Abstract][Full Text] [Related]
7. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption. Klingel R; Heibges A; Fassbender C Atheroscler Suppl; 2013 Jan; 14(1):161-5. PubMed ID: 23357159 [TBL] [Abstract][Full Text] [Related]
12. [The use of therapeutic apheresis in neurological diseases and comparison between plasma exchange and immunoadsorption]. Loschiavo C; Grecò M; Polo A; Del Colle R G Ital Nefrol; 2015; 32(1):. PubMed ID: 25774587 [TBL] [Abstract][Full Text] [Related]
13. Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications. Fuchs K; Rummler S; Ries W; Helmschrott M; Selbach J; Ernst F; Morath C; Gauly A; Atiye S; Stauss-Grabo M; Giefer M Ther Apher Dial; 2022 Feb; 26(1):229-241. PubMed ID: 33914397 [TBL] [Abstract][Full Text] [Related]